Abstract:Following the publication of this article, an interested reader drew to our attention anomalies associated with the data shown in Fig. 2, which presented the mRNA and protein expression levels of tropomyosin 1 (TPM1) in HuCCT1 cells. Essentially, the control bands for α-tubulin had been duplicated across from Fig. 2A to Fig. 2B, and from Fig. 2D to Fig. 2E [the experiments showing treatment of the cells with (A) manumycin A, (B) U0126, (D) 5-aza-2-deoxycytidine (DAC) and (E) trichostatin A (TSA)], respectively. After having re‑examined our original data, we realize that the figure was compiled incorrectly, and have returned to our source data. A corrected version of Fig. 2 is presented here, showing the correct control α-tubulin data for Fig. 2A and E, as they ought to have appeared. This error did not overall affect the conclusions reported in the study. We sincerely apologize for this mistake, and thank the reader of our article who drew this matter to our attention. Furthermore, we regret any inconvenience this mistake has caused. [the original article was published in the International Journal of Oncology 42: 690-698, 2013; DOI: 10.3892/ijo.2012.1741].

Dihydroartemisinin Inhibits Tctp-Dependent Metastasis In Gallbladder Cancer (Vol 36, 68, 2017)

Correction to: Cryptotanshinone activates AMPK-TSC2 axis leading to inhibition of mTORC1 signaling in cancer cells

Artemisinin Derivatives Inactivate Cancer-Associated Fibroblasts Through Suppressing TGF-β Signaling in Breast Cancer

Mir-148b Suppresses Cell Proliferation And Invasion In Hepatocellular Carcinoma By Targeting Wnt1/Beta-Catenin Pathway (Vol 5, 8087, 2015)

Erratum: Targeting NF-κB/AP-2β Signaling to Enhance Antitumor Activity of Cisplatin by Melatonin in Hepatocellular Carcinoma Cells.

Correction To: Early Presence of Anti-Angiogenesis-related Adverse Events As a Potential Biomarker of Antitumor Efficacy in Metastatic Gastric Cancer Patients Treated with Apatinib: a Cohort Study

Erratum: Artemin is estrogen regulated and mediates antiestrogen resistance in mammary carcinoma

Genetic and epigenetic alterations are involved in the regulation of TPM1 in cholangiocarcinoma

The tumor suppressive miR-302c-3p inhibits migration and invasion of hepatocellular carcinoma cells by targeting TRAF4: Erratum

Correction: Dihydroartemisinin inhibits prostate cancer via JARID2/miR-7/miR-34a-dependent downregulation of Axl

Correction To: Methylseleninic Acid Suppresses Breast Cancer Growth Via the JAK2/STAT3 Pathway

Author Correction: Cantharidin represses invasion of pancreatic cancer cells through accelerated degradation of MMP2 mRNA

Correction: Primary Tumor-Derived Exosomes Facilitate Metastasis by Regulating Adhesion of Circulating Tumor Cells Via SMAD3 in Liver Cancer

Corrigendum: Isorhamnetin Inhibits Human Gallbladder Cancer Cell Proliferation and Metastasis via PI3K/AKT Signaling Pathway Inactivation

Correction: Efficacy of transcatheter arterial chemoembolization for liver metastases arising from pancreatic cancer.

Correction: Shi, H., et al. Arctigenin Attenuates Breast Cancer Progression through Decreasing GM-CSF/TSLP/STAT3/β-Catenin Signaling. Int. J. Mol. Sci. 2020, 21, 6357

[Corrigendum] Antiproliferative effect of alpinetin in BxPC-3 pancreatic cancer cells

[Corrigendum] Celecoxib inhibits the epithelial‐to‐mesenchymal transition in bladder cancer via the miRNA‐145/TGFBR2/Smad3 axis

Corrigendum: β-Sitosterol and Gemcitabine Exhibit Synergistic Anti-Pancreatic Cancer Activity by Modulating Apoptosis and Inhibiting Epithelial–Mesenchymal Transition by Deactivating Akt/GSK-3β Signaling

Dihydroartemisinin suppresses bladder cancer cell invasion and migration by regulating KDM3A and p21

Supplementary Figure 3 from CXCR6 Upregulation Contributes to a Proinflammatory Tumor Microenvironment That Drives Metastasis and Poor Patient Outcomes in Hepatocellular Carcinoma